NewsBenzingaArgenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development Benzinga 2026.10.08 05:40 (GMT+0) Open on Benzinga Other news EVgo Q2 2026 Earnings Call: Complete Transcript Geron Q2 2026 Earnings Call: Complete Transcript NCR Voyix Q2 2026 Earnings Call Transcript Lifecore Biomedical Q2 2026 Earnings Call Transcript HTX Lists AKAM, VKTX, H100, FOXA, INTU, CT Perpetual Contracts Full Transcript: Teleflex Q2 2026 Earnings Call
